Evidence map›Paper›PMID 36159859›Full record

ArticleFrontiers in immunology2022

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity.

Arne Søraas, Gunnveig Grødeland, Beathe Kiland Granerud, Thor Ueland, Andreas Lind, Børre Fevang, Sarah L Murphy, Camilla Huse, Anders Benteson Nygaard, Anne Katrine Steffensen and 22 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 2 institutions in 1 country.

Arne SøraasDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Gunnveig GrødelandDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Beathe Kiland GranerudDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Thor UelandInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Andreas LindDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Børre FevangResearch Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Sarah L MurphyInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Camilla HuseInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Anders Benteson NygaardDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Anne Katrine SteffensenDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Huda Al-BaldawiInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Mona Holberg-PetersenDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Lise Lima AndresenDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Camilla ÅgnesResearch Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Trine RanheimResearch Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Ylva SchankeResearch Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Mette IstreDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
John Arne DahlDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Adity ChopraDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Susanne DudmanDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Mari KaarbøDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Jan Terje AndersenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Eline Benno VaageDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Trung The TranDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
John Torgils VaageDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Annika E MichelsenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Fredrik MüllerDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Pål AukrustInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Bente HalvorsenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
Tuva B DahlResearch Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.
Jan Cato HolterDepartment of Microbiology, Oslo University Hospital, Oslo, Norway.
Fridtjof Lund-JohansenDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant. Funding: The study was funded by the Oslo University Hospital, and by grants from The Coalition for Epidemic Preparedness Innovations, Research Council of Norway (no 312780, 324272), South-Eastern Norway Regional Health Authority (no 2019067, 2021071, 10357, 2021047, 33612, 2021087, 2017092), EU Horizon 2020 grant no 848099, a philantropic donation from Vivaldi Invest A/S, and The European Virus Archive Global.

Indexed as

COVID-19Viral VaccinesAntibodies, ViralHumansInflammation MediatorsInterferon-gammaNucleocapsid ProteinsSARS-CoV-2Antibodies, ViralInflammation MediatorsInterferon-gammaNucleocapsid ProteinsViral VaccinesantibodyBreakthrough infectioncellular immunityhumanSARS-CoV-2vaccine

Identifiers

PMID36159859
PMCPMC9493489
OpenAlexW4296101111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.